JAKAFI

JAKAFI- ruxolitinib tablet
Incyte Corporation

1. INDICATIONS AND USAGE

1.1 Myelofibrosis

Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults.

1.2 Polycythemia Vera

Jakafi is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.

1.3 Acute Graft Versus Host Disease

‚Äč Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.

2. DOSAGE AND ADMINISTRATION

2.1 Myelofibrosis

The recommended starting dose of Jakafi is based on platelet count (Table 1). A complete blood count (CBC) and platelet count must be performed before initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as clinically indicated [see Warnings and Precautions (5.1) ]. Doses may be titrated based on safety and efficacy.

Table 1: Jakafi Starting Doses for Myelofibrosis
Platelet Count Starting Dose
Greater than 200 X 109 /L 20 mg orally twice daily
100 X 109 /L to 200 X 109 /L 15 mg orally twice daily
50 X 109 /L to less than 100 X 109 /L 5 mg orally twice daily

Dose Modification Guidelines for Hematologic Toxicity for Patients with Myelofibrosis Starting Treatment with a Platelet Count of 100 X 109 /L or Greater

Treatment Interruption and Restarting Dosing

Interrupt treatment for platelet counts less than 50 X 109 /L or absolute neutrophil count (ANC) less than 0.5 X 109 /L.

After recovery of platelet counts above 50 X 109 /L and ANC above 0.75 X 109 /L, dosing may be restarted. Table 2 illustrates the maximum allowable dose that may be used in restarting Jakafi after a previous interruption.

Table 2: Myelofibrosis: Maximum Restarting Doses for Jakafi after Safety Interruption for Thrombocytopenia for Patients Starting Treatment with a Platelet Count of 100 X 109 /L or Greater
*
Maximum doses are displayed. When restarting, begin with a dose at least 5 mg twice daily below the dose at interruption.
Current Platelet Count Maximum Dose When Restarting Jakafi Treatment *
Greater than or equal to 125 X 109 /L 20 mg twice daily
100 to less than 125 X 109 /L 15 mg twice daily
75 to less than 100 X 109 /L 10 mg twice daily for at least 2 weeks; if stable, may increase to 15 mg twice daily
50 to less than 75 X 109 /L 5 mg twice daily for at least 2 weeks; if stable, may increase to 10 mg twice daily
Less than 50 X 109 /L Continue hold

Following treatment interruption for ANC below 0.5 X 109 /L, after ANC recovers to 0.75 X 109 /L or greater, restart dosing at the higher of 5 mg once daily or 5 mg twice daily below the largest dose in the week prior to the treatment interruption.

Dose Reductions Dose reductions should be considered if the platelet counts decrease as outlined in Table 3 with the goal of avoiding dose interruptions for thrombocytopenia.

Table 3: Myelofibrosis: Dosing Recommendations for Thrombocytopenia for Patients Starting Treatment with a Platelet Count of 100 X 109 /L or Greater
Dose at Time of Platelet Decline
Platelet Count 25 mg twicedaily 20 mg twicedaily 15 mg twicedaily 10 mg twicedaily 5 mg twicedaily
NewDose NewDose NewDose NewDose NewDose
100 to less than 125 X 109 /L 20 mg twicedaily 15 mg twicedaily No Change No Change No Change
75 to less than 100 X 109 /L 10 mg twicedaily 10 mg twicedaily 10 mg twicedaily NoChange NoChange
50 to less than 75 X 109 /L 5 mg twicedaily 5 mg twicedaily 5 mg twicedaily 5 mg twicedaily NoChange
Less than 50 X 109 /L Hold Hold Hold Hold Hold

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.